Evaluation of efficacy in improvement of cardiac function / renal function by REZALTAS COMBINATION TABLETS on hypertension patient. - Evaluation of efficacy of REZALTAS COMBINATION TABLETS on hypertension patient.

Start Date01 Mar 2011

Sponsor / Collaborator

Kanazawa University Hospital

JPRN-jRCT2080220439 / Unknown statusPhase 3

Open-label, phase III study of CS-866AZ

Start Date12 Sep 2007

Sponsor / Collaborator-

NCT00454662 / CompletedPhase 4IIT

Combination of OLMesartan and Calcium Channel Blocker or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study)

The purpose of this study is to investigate which combination therapy is more effective in reducing the incidence of cardiovascular events in Japanese elderly high-risk hypertensive patients: AT1 subtype angiotensin II receptor antagonist/calcium channel blocker or AT1 subtype angiotensin II receptor antagonist/low dose diuretic.

Start Date01 Apr 2007

Sponsor / Collaborator

Japan Heart Foundation

100 Clinical Results associated with Olmesartan Medoxomil/Azelnidipine

100 Translational Medicine associated with Olmesartan Medoxomil/Azelnidipine

100 Patents (Medical) associated with Olmesartan Medoxomil/Azelnidipine

Literatures (Medical) associated with Olmesartan Medoxomil/Azelnidipine

01 Jan 2020·AAPS PharmSciTech

Chronological Delivery of Antihypertensive Drugs in Bilayered Core-in-Cup Buccoadhesive Tablets: In Vitro and In Vivo Evaluation

Article

Author: Nageeb El-Helaly, Sara ; Rashad, Amira A ; El-Gazayerly, Omaima N ; Abd El Rehim, Randa T

Hypertension shows circadian blood pressure rhythms (day-night pattern) that urge the delivery of antihypertensive drugs at the right time in the desired levels. Thus, a bilayered core-in-cup buccoadhesive tablet was formulated that immediately releases olmesartan, to give a burst effect, and controls azelnidipine release, to prolong its therapeutic effect. The main challenge was the poor bioavailability of azelnidipine due to its poor aqueous solubility and first-pass effect. Hence, liquisolid compact buccoadhesive tablets were prepared to enhance solubility, dissolution profiles, and bypass the oral route. Two factorial designs were conducted to study the type and concentration effect of the mucoadhesive polymers on the dissolution and mucoadhesion of olmesartan and azelnidipine. Characterization studies were conducted regarding drug content, surface pH, water uptake, mucoadhesive strength, in vitro release, and ex vivo permeability. The core-in-cup olmesartan/azelnidipine buccoadhesive tablet showed similar release profile to the statistically optimized formulae of each drug. In vitro dissolution study showed enhanced release of azelnidipine than the directly compressed tablets, to comply with the regulatory standards of controlled release systems. In vivo pharmacokinetic study of olmesartan and azelnidipine conducted on human volunteers against Rezaltas® 10/8 mg tablet showed percentage relative bioavailability of 106.12 and 470.82%, respectively. Graphical Abstract.

100 Deals associated with Olmesartan Medoxomil/Azelnidipine

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	C09D	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hypertension	JP	Daiichi Sankyo Co., Ltd.	20 Jan 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ISC2020	Not Applicable	Post-stroke Fatigue	36	Olmesartan/Azelnidipine combination	(cltypnmzcs) = ikxxnlyxrn mxsaurhxyw (eudmvqnfql )	-	01 Feb 2020
				High-dose olmesartan	(cltypnmzcs) = bwmhgielzx mxsaurhxyw (eudmvqnfql )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis